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Abstract
Background: Nevirapine has been used as antiretroviral agent since early ‘90. Although nevirapine is not currently
recommended in initial anti-HIV regimens, its use remains consistent in a certain number of HIV-1-positive subjects.
Thus, our aim was to determine clinical and genetic factors involved in the development of severe nevirapine
induced liver toxicity.
Methods: We retrospectively analyzed all HIV positive patients who were followed at the Infectious Diseases Unit,
DIBIC Luigi Sacco, University of Milan from May 2011 to December 2015. All patients treated with nevirapine who
underwent a genotyping for the functional variants mapping into ABCB1, CYP2B6, CYP3A4 and CYP3A5 genes were
included in the analysis. Severe hepatotoxicity was defined as ACTG grade 3–4 AST/ALT increase during the first
three months of nevirapine treatment. The causality assessment between NVP exposure and drug-induced liver
injury was performed by using the updated Roussel Uclaf Causality Assessment Methods. Hardy Weinberg
equilibrium was tested by χ2 test. A multivariable logistic regression model was constructed using a backward
elimination method.
Results: Three hundred and sixty-two patients were included in the analysis, of which 8 (2.2%) experienced a severe
liver toxicity. We observed no differences between patients with and without liver toxicity as regards gender, ethnicity,
age and immune-virological status. A higher prevalence of HCV coinfection (75.0% vs 30.2%; p = .0013) and higher
baseline AST (58 IU/L vs 26 IU/L; p = 0.041) and ALT (82 IU/L vs 27 IU/L; p = 0.047) median levels were observed in
patients with liver toxicity vs those without toxicity. The genotypes CT/TT at ABCB1 rs1045642 single nucleotide
polymorphism (SNP), showed a protective effect for liver toxicity when compared with genotype CC (OR = 0.18, 95%CI
0.04–0.76; p = 0.020) in univariate analysis. In the multivariate model, HCV coinfection was independently associated
with higher risk of developing liver toxicity (aOR = 8.00, 95%CI 1.27–50.29; p = 0.027), whereas ABCB1 rs1045642 CT/TT
genotypes (aOR = 0.10, 95%CI 0.02–0.47; p = 0.004) was associated with a lower risk.
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Conclusions: According to our findings HCV coinfection and ABCB1 rs1045642 SNP represent independent
determinants of severe liver toxicity related to nevirapine. This genetic evaluation could be included as toxicity
assessment in HIV-1-positive subjects treated with nevirapine.
Keywords: Nevirapine, Pharmacogenetic, Hepatotoxicity, ABCB1
Background
Nevirapine (NVP) is a potent non-nucleoside reverse
transcriptase inhibitor widely prescribed in low-income
countries for HIV treatment and prevention of mother-
to-child transmission of HIV [1]. In high-resource coun-
tries, NVP is no longer included among antiretrovirals
recommended for initial antiretroviral treatment (ART),
although it still remains a valid component of regimens
used as ART simplification strategy due to its high
efficacy, good metabolic profile, convenience, and low
cost [2–4].
Although generally well tolerated and effective, some
individuals exposed to NVP develop in the short-term
hypersensitivity reactions which can manifest as hepato-
toxicity and/or severe cutaneous adverse reactions [5].
Hepatotoxicity, in particular, has been reported more
commonly with NVP than with other antiretroviral
drugs [6, 7]. Higher baseline and nadir CD4 cell count
have been found to independently influence the risk of
NVP-related adverse reactions and the use of NVP in
naive women (with CD4 > 250 cells/uL) and males (with
CD4 > 400 cells/uL) is disallowed [8]. The role of the im-
mune system, i.e. higher CD4 cells count, in the devel-
opment of NVP induced skin and liver toxicity is
corroborated by the higher incidence of these events in
HIV negative patients receiving NVP as a component of
post exposure prophylaxis [5]. Nevertheless, when NVP
is used in ART-experienced patients with a controlled
viremia the risk of development hepatic or cutaneous
adverse events significantly decrease and there is no evi-
dent association with CD4 cell count [9–11].
A series of demographic and clinical factors have been
found to correlate with an increased risk of
NVP-toxicity. In particular, risk factors for ALT and AST
elevations during NVP therapy included alteration of
liver enzymes before NVP start, co-infection with hepa-
titis B or hepatitis C viruses, female gender and low body
weight [6, 12].
A number of studies have also investigated the pos-
sible predictive role of genetic polymorphisms of CYP
enzymes or drug-transporters involved in NVP metabol-
ism in predisposing to NVP-related adverse effects. NVP
is metabolized by cytochrome P450 enzymes CYP2B6
and CYP3A4 with a minor contribution from CYP3A5
[13]. Single nucleotide polymorphisms (SNPs) have been
found to impact NVP pharmacokinetics in ethnic mix
populations [14–16]. The genotype TT (c.516/
rs3745274) in the CYP2B6 gene, in particular, has been
associated with higher plasma concentrations of NVP
and its possible role in increasing the risk of hepatotox-
icity has been hypothesized [14]. However, there is con-
trasting evidence of interactions between the presence of
variant alleles of CYP2B6 and the development of
NVP-induced hepatotoxicity [17–19]. The role of
CYP3A4 and CYP3A5 variants in determining NVP
plasma concentration and the development of liver tox-
icity is more controversial, with only one report of asso-
ciation between CYP3A5 variants and transaminase
values in African patients exposed to NVP [20]. More-
over, although effects of the efflux transporter
P-glycoprotein encoded by the ATP Binding Cassette
Subfamily B Member 1 (ABCB1) gene on NVP pharma-
cokinetics remains controversial, two studies have found
a protective effect of ABCB1 c.3435 T allele against
NVP-related hepatotoxicity [19, 20].
The majority of the studies that evaluated the correl-
ation between pharmacogenetic profiles and
NVP-related hepatotoxicity have been performed mainly
on African population. However, genetic variant fre-
quencies can differ markedly between different popula-
tions and only few data are available on the mentioned
pharmacogenetic profiles in non-African populations.
With this in mind, we assessed clinical and pharmaco-
genetic factors associated with the risk of severe NVP in-
duced liver toxicity in a population of HIV-positive
patients attending a clinical center in Italy.
Methods
This study was conducted on a cohort of adult
HIV-positive patients attending the Infectious Diseases
Unit, DIBIC Luigi Sacco, University of Milan between
May 1 2011 and December 31 2015. Patients who have
ever received or were receiving a NVP-containing cART
at our clinical center were eligible for the analysis.
Patient’s demographic (age, gender, and ethnicity), epi-
demiological (HIV acquisition risk) and clinical (CDC
stage, body mass index, coinfections, previous and
current antiretroviral regimens, immune-virological and
hemato-biochemical parameters) data registered during
medical visits (on average every three months) are
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routinely collected in a structured database, allowing the
use of the database for clinical, epidemiological or thera-
peutic studies.
Severe hepatotoxicity was defined as ACTG grade 3–4
AST and/or ALT increase (AST or ALT elevation above
5 time the upper reference limit) during the first three
months of nevirapine treatment. The causality assess-
ment between NVP exposure and drug-induced liver in-
jury was performed by using the updated Roussel Uclaf
Causality Assessment Methods (RUCAM) [21]. Accord-
ing to the RUCAM, patients were firstly assessed for he-
patocellular, cholestatic or mixed liver injury.
Subsequently, the score was applied and single cases of
NVP-induced liver injury were classified accordingly to
the RUCAM total score interpretation and causality
grading: ≤0, excluded; 1–2, unlikely; 3–5, possible; 6–8,
probable and ≥ 9 highly probable [21].
All patients who met the inclusion criteria underwent
a genotyping for the functional variants mapping in
ABCB1 (c.3435/rs1045642), CYP2B6 (c.516/rs3745274),
CYP3A5 (*3/rs776746) and CYP3A4 (*22/rs35599367)
genes. Genomic DNA was isolated from peripheral
blood cells using an automatic DNA extraction system
(Maxwell® 16 System, Promega) according to the manu-
facturer’s instructions. All genotypes were determined by
Real-Time PCR, using a panel of LightSNiP from
TIB-MolBiol (assays based on SimpleProbe®). At the end
of the amplification a melting curve analysis was per-
formed (LightCycler 480, Roche).
Statistical analysis
Baseline clinical characteristics and genotypes of the two
groups of interest, i.e. patients who developed severe hep-
atotoxicity and those who did not, were compared using
the χ2 or Fisher’s exact test for categorical variables and
the Mann-Whitney test for continuous variables.
Hardy Weinberg equilibrium was tested by χ2 test.
The association of clinical and genotypic variables with
the development of sever liver toxicity was tested by
means of a univariate logistic regression model, and all
variables were incorporated into a multivariate logistic re-
gression model with a backward elimination method. Stat-
istical significance was defined at 2-sided P value < 0.05.
The risks were expressed as adjusted odds ratios (aOR)
with relative confidence intervals (95% CI). To perform
statistical analysis we used the SAS software version 9.3.
The study was reviewed and approved by our ethics
committee (Comitato Etico Interaziendale, Milano area
1); all subjects signed a dedicated informed consent.
Results
A total of 362 patients were included in the analysis.
Most of them were ART-experienced at the time of initi-
ation of NVP-containing regimen, whereas a minority
(16.1%) were ART-naïve. Overall 8 (2.2%) patients expe-
rienced a severe liver toxicity during the first three
months from NVP initiation. Table 1 shows the com-
parison of patients who experienced a severe hepatotox-
icity and those who did not. There was no significant
difference as regards gender, ethnicity, age and baseline
immune-virological status between the two groups al-
though females showed a trend towards a higher fre-
quency of NVP-induced hepatotoxicity (75.0% vs 35.9%;
p = 0.055). Conversely, patients who developed severe
hepatotoxicity were more frequently HCV-coinfected
(75.0% vs 30.2%: p = 0.013), showed higher baseline AST
and ALT median levels (58 IU/L vs 26 IU/L p = 0.041,
82 IU/L vs 27 IU/L p = 0.047, respectively), and a lower
median baseline body mass index value (19.9 kg/m2 vs
22.6 kg/m2; p = 0.017).
According to RUCAM, the 8 cases of NVP-induced
liver toxicity were classified as hepatocellular injury and
the likelihood of NVP-induced liver toxicity resulted
possible for 3 patients and probable for 5 patients as
shown in Table 2. A brief narration for each of the 8
cases is reported in Table 3.
Distribution of different genotypes of ABCB1
rs1045642, CYP2B6 rs3745274 and CYP3A4/A5 com-
bined are shown in Table 4. A statistical significant dif-
ference was observed in patient with and without
NVP-induced hepatotoxicity according to ABCB1
rs1045642 genotypes (p = 0.019).
In univariate analysis (Table 5), male gender (OR =
0.19 95%CI 0.04–0.94; p = 0.042), HCV coinfection (OR
= 6.93 95%CI 1.38–34.87; p = 0.019), AST (OR = 1.02,
95%CI 1.01–1.03; p = 0.008) and ALT (OR = 1.01, 95%CI
1.00–1.02; p = 0.015) median level at the beginning of
NVP have been associated with an increased risk of se-
vere NVP-induced liver toxicity. On the other hand, ge-
notypes CT/TT of ABCB1 rs1045642 (OR = 0.18, 95%CI
0.04–0.76; p = 0.020) and greater value of body mass
index (OR = 0.7 95%CI 0.51–0.94, p = 0.02) showed a
protective effect.
In the multivariate logistic regression model (Table 5),
HCV coinfection was confirmed to be independently as-
sociated with a higher risk of developing liver toxicity
(aOR = 8.00, 95%CI 1.27–50.29; p = 0.027), whereas
ABCB1 CT/TT genotypes (aOR = 0.10, 95%CI 0.02–0.47;
p = 0.004) has been associated with a lower risk; a
higher body mass index (aOR = 0.72, 95%CI 0.519–
1.000; p = 0.050) has been barely related to a lower risk
(Table 5). On the contrary, the association between
gender, baseline AST levels and NVP-induced liver tox-
icity wasn’t confirmed in the final multivariate model.
Discussion
In this study conducted in a monocentric cohort of
HIV-1 positive patients exposed to NVP we observed,
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during the first three months of treatment, an incidence
of severe liver toxicity of 2.2%. This finding is similar to
that reported by other cohorts when NVP was used in ex-
perienced patients [10, 22]. We did not observe a signifi-
cant association between the development of
hepatotoxicity and high CD4 cells count at NVP start, sup-
porting the observation of low frequency of NVP induced
liver toxicity in experienced patients [10]. The mechanisms
involved in the development of severe hepatotoxicity are
not well explained and it could be that in patients never
exposed to antiretroviral therapy immune-mediated
process leading to immune-reconstitution could elicit the
development of liver toxicity [23]. On the contrary, in ex-
perienced patients with a stable immune-virological situ-
ation, hepatotoxicity could be driven by a direct effect of
the drug in susceptible patients [24]. We confirm previous
findings supporting the importance of HCV coinfection as
independent factor associated to the development of
NVP-related liver toxicity; HCV infection could play a dir-
ect role causing liver injury and also could interfere with
the metabolism of the drug [8, 11, 25]. The enhanced risk
of development hepatotoxicity in HCV coinfected patients
treated with NVP seems to be independent from NVP
plasmatic concentrations, since comparable NVP concen-
tration are observed in patients with and without HCV co-
infection [26].
A significant correlation between low value of body
mass index (< 18.5) such as for increased NVP plasma
concentration and increased risk for hepatotoxicity has
been previously reported [12, 18], in our study we ob-
served a trend of body weight in predisposing to
NVP-hepatotoxicity albeit not confirmed in the multi-
variate model.
In accordance with previous studies, we did not found a
statistically significant association between polymorphisms
in CYPs genes (CYP2B6, CYP3A4, CYP3A5) and the de-
velopment of severe hepatotoxicity. Although these genes
are involved in NVP metabolism [27] and their functional
variants may significantly affect NVP plasma concentra-
tions [28–30], their role in predisposing NVP induced
hepatotoxicity remains unclear [19, 31].
The ABCB1 gene encodes for P-glycoprotein, one of
the most important efflux pomp involved in the trans-
port of both NVP and efavirenz and a modification of
this protein could determine an alteration in the intra-
cellular concentration of these drugs [32].
Table 1 Baseline characteristics
Total
n = 362
Hepatotoxicity
n = 8
No hepatotoxicity
n = 354
p*
Age, median (IQR) 38.5 (33.7–45.8) 39.6 (32.7–40.7) 38.5 (33.8–45.9) 0.479
Female, n (%) 133 (36.7) 6 (75.0) 127 (35.9) 0.055
Naïve patients, n (%) 58 (16.0) 1 (12.5) 57 (16.1) 0.783
Risk group, n (%)
Eterosexual 181 (50.0) 4 (50.0) 177 (50.0) 0.213
MSM 83 (22.9) 0 (0.0) 83 (23.5)
IVDUs 84 (23.2) 4 (50.0) 80 (22.6)
Others 14 (3.9) 0 (0.0) 14 (3.9)
Caucasian, n (%) 330 (91.1) 7 (87.5) 323 (91.2) 0.527
BMI, median (IQR) 22.4 (20.5–24.5) 19.9 (18.3–22.0) 22.6 (20.6–24.5) 0.017
AIDS, n (%) 63 (17.4) 1 (12.5) 62 (17.5) 0.999
CD4+/mL, median (IQR) 436 (306–593) 555 (479–611) 433 (300–592) 0.157
HIV-RNA log10 cp/mL,median (IQR) 1.75 (0.00–4.09) 0.00 (0.00–2.16) 1.79 (0.00–4.10) 0.229
HCV coinfection, n (%) 131 (31.2) 6 (75.5) 107 (30.2) 0.013
HBV coinfection, n (%) 21 (5.8) 1 (12.5) 20 (5.65) 0.383
AST U/L, median (IQR) 26 (20–38) 58 (29–92) 26 (20–37) 0.041
ALT U/L, median (IQR) 28 (18–50) 82 (37–122) 27 (18–49) 0.047
ARV backbone, n (%)
ABC 32 (8.8) 1 (12.5) 31 (8.8) 0.311
AZT/DDI/D4T 223 (61.6) 7 (87.5) 216 (61.0)
TDF 86 (23.7) 0 (0.0) 86 (24.3)
Others 21 (5.8) 0 (0.0) 21 (5.9)
Abbreviations: n number, yrs. years, IQR Inter Quartile Range, MSM Man how have sex with man, IVDUs Intra venous drug users, BMI Body Mass Index, cps copies,
ABC abacavir, TDF tenofovir diproxil fumarate. *p-values are for χ2 or Fisher’s exact test and Mann-Whitney test
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Table 2 Updated RUCAM for the nevirapine-induced hepatocellular injury with the total scores for each patient
RUCAM items Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8
1. Time to onset from the beginning of the drug
• 5–90 days (rechallenge: 1–15 days) (+ 2)
• < 5 or > 90 days (rechallenge: > 15 days) (+ 1)
Alternative: Time to onset from cessation of the drug
• ≤15 days (except for slowly metabolized chemicals: > 15 days) (+ 1)
+ 2 + 2 + 2 + 2 + 2 + 2 + 2 + 2
2. Course of ALT after cessation of the drug
• Percentage difference between ALT peak and N
• Decrease ≥50% within 8 days (+ 3)
• Decrease ≥50% within 30 days (+ 2)
• No information or continued drug use (0)
• Decrease ≥50% after the 30th day (0)
• Decrease < 50% after the 30th day or recurrent increase (− 2)
+ 2 + 2 + 2 + 2 + 2 + 3 + 2 0
3. Risk factors
• Alcohol use (current drinks/d: > 2 for women, > 3 for men) (+ 1)
• Alcohol use (current drinks/d: ≤2 for women, ≤3 for men) (0)
• Age≥ 55 years (+ 1)
• Age < 55 years (0)
0 0 + 1 0 + 1 + 0 0 0
4. Concomitant drug(s)
• None or no information (0)
• Concomitant drug/herb with incompatible time to onset (0)
• Concomitant drug/herb with compatible or suggestive time to onset (1)
• Concomitant drug/herb known as hepatotoxin and with compatible
or suggestive time to onset delete marking right side above (− 2)
• Concomitant drug/herb with evidence for its role in this case
(positive rechallenge or validated test) (− 3)
0 0 − 2 0 0 0 0 0
5. Search for alternative causes Tick if negative Tick if not done
Group I (7 causes)
• HAV: Anti-HAV-IgM
• Hepatobiliary sonography / colour Doppler
• HCV: Anti-HCV, HCV-RNA
• HEV: Anti-HEV-IgM, anti-HEV-IgG, HEV-RNA
• Hepatobiliary sonography/colour Doppler sonography of liver
vessels/endosonography/CT/MRC
• Alcoholism (AST/ALT ≥2)
• Acute recent hypotension history (particularly if underlying heart disease)
Group II (5 causes)
• Complications of underlying disease(s) such as sepsis,
metastatic malignancy, autoimmune hepatitis, chronic hepatitis B or C,
primary biliary cholangitis or sclerosing cholangitis, genetic liverdiseases
• Infection suggested by PCR and titer change for
- CMV (anti-CMV-IgM, anti-CMV-IgG)
- EBV (anti-EBV-IgM, anti-EBV-IgG)
- HSV (anti-HSV-IgM, anti-HSV-IgG)
- VZV (anti-VZV-IgM, anti-VZV-IgG)
Evaluation of groups I and II
• All causes-groups I and II—reasonably ruled out (+ 2)
• The 7 causes of group I ruled out (+ 1)
• 6 or 5 causes of group I ruled out (0)
• Less than 5 causes of group I ruled out (− 2)
• Alternative cause highly probable (− 3)
0 0 0 0 −2 + 1 0 0
6. Previous hepatotoxicity of the drug
• Reaction labelled in the product characteristics (+ 2)
• Reaction published but unlabelled (+ 1)
• Reaction unknown (0)
+ 2 + 2 + 2 + 2 + 2 + 2 + 2 + 2
7. Response to unintentional reexposure
• Doubling of ALT with the drug/herb alone, provided ALT
below 5 N before reexposure (+3)
• Doubling of ALT with the drug(s)/herb(s) already given
at the time of first reaction (+ 1)
• Increase of ALT but less than N in the same conditions
as for the first administration (−2)
• Other situations (0)
0 0 0 0 0 0 0 0
Total + 6 + 6 + 5 + 6 + 5 + 8 + 6 + 4
Abbreviations: pt. Patient, ALT Alanine aminotransferase, AST Aspartate aminotransferase, CMV Cytomegalovirus, CT Computer tomography, EBV Epstein
Barr virus, HAV Hepatitis A virus, HBc Hepatitis B core, HBsAg Hepatitis B antigen, HBV Hepatitis B virus, HCV Hepatitis C virus, HEV Hepatitis E virus, HSV
Herpes simplex virus, MRC Magnetic resonance cholangiography, N upper limit of the normal range, RUCAM Roussel Uclaf Causality Assessment
Method, VZV Varicella zoster virus
Total score and resulting causality grading: ≤0, excluded; 1–2, unlikely; 3–5, possible; 6–8, probable; and ≥ 9, highly probable
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Interestingly, the functional variant c.3435 C > T of
ABCB1 gene was associated with an increases risk for se-
vere liver toxicity in a previous study conducted by Hass
et al. in South-Africa [19]. Moreover, the variant ABCB1
c.3435 C > T resulted protective for NVP-associated hep-
atic adverse events in another study conducted in
Mozambique [20]. No statistically significant association
between ABCB1 c.3435 C > T and NVP adverse events
was found in another study conducted by Yuan J et al. in
an ethnic mixed population. However, these authors found
a significant association between ABCB1 c.3435 C > T
variant and hepatic adverse events among Africans but
not Asians or Caucasians, despite these latter groups
showed increased T-allele frequencies [31].
Overall our study, which was conducted on a prevalently
European Caucasian population, disagrees with the study
by Yan et al. On the contrary it supports the protective role
of T allele of ABCB1 rs1045642 for NVP-hepatotoxicity
evidenced by Hass et al. and Ciccacci et al.
The present study has some limitations. In particular, due
to the retrospective design we cannot exclude the presence
of possible bias related to loss of data. A sub-optimal per-
formance of RUCAM, which is more fitted for a prospect-
ive patient evaluation, could be hypothesized because of the
Table 3 Clinical characteristics of the 8 cases of NVP-induced liver injury. *HLAB5701 tested absent
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8
HCV coinfection no yes yes yes yes no yes yes
ARV status Experienced Experienced Experienced Experienced Naive Experienced Experienced Experienced
Concomitant ARV d4T + 3TC d4T + 3TC ABC* + 3TC AZT + 3TC AZT + 3TC d4T + ddi AZT + 3TC d4T + ddi
NVP exposure before
treatment interruption
(days)
28 61 29 28 58 28 50 38
Concomitant medication none none Vitamin D and
folinic acid
none Phenobarbital
and alprazolam
none None Folinic acid
Symptoms Nausea
and severe
weakness
none Nausea none Weakness none Nausea None
Required hospitalization yes no yes no no no no no
Outcome Recovered
without
sequelae
Recovered
without
sequelae
Recovered
without
sequelae
Recovered
without
sequelae
Recovered
without
sequelae
Recovered
without
sequelae
Recovered
without
sequelae
Recovered
without
sequelae
RUCAM Probable Probable Possible Probable Possible Probable Probable Possible
Abbreviations: Pt Patient, HCV Hepatitis C virus, ARV Antiretroviral, d4T Stavudine, 3TC Lamivudine, ABC Abacavir, AZT Zidovudine, ddi Didanosine, RUCAM Roussel
Uclaf Causality Assessment Method
Table 4 Disposition of polymorphisms involved in nevirapine metabolism
Total Hepatotoxicity No hepatotoxicity p*
n = 362 n = 8 n = 354
ABCB1 c.3435/rs1045642, n (%) 0.019
CC 86 (23.8) 5 (5.8) 81 (94.2)
CT 178 (49.2) 1 (0.6) 177 (99.4)
TT 98 (27.0) 2 (2.0) 96 (98.0)
CYP2B6 c.516/rs3745274, n (%) 0.706
GG 196 (54.1) 6 (3.1) 190 (96.9)
GT 141 (39.0) 2 (1.4) 139 (98.6)
TT 25 (6.9) 0 (0.0) 25 (100.0)
CYP3A4/A5 **, n (%) 0.602
Extensive 58 (16.1) 0 (0.0) 58 (100.0)
Intermediate 270 (74.5) 8 (3.0) 262 (97.0)
Poor 25 (6.9) 0 (0.0) 25 (100.0)
nd 9 (2.5) 0 (0.0) 9 (100.0)
Abbreviations: n number, nd not determined, ABCB ATP Binding Cassette Subfamily B, CYP Cytochrome P450 enzyme
*χ2 test ** CYP3A4*22/rs35599367 and CYP3A5*3/rs776746 combined genotypes for comprehensive functional evaluation [33, 34]
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retrospective nature of the study. Moreover, if on one hand
the limited number of NVP induced hepatic adverse events
supports the good safety profile of this drug in
ART-experienced patients, on the other hand our study
could not exclude that the prevalence of the investigated
polymorphisms could be driven by chance. Moreover, the
prevalence of Caucasian ethnicity limited the comparison
of our findings between different ethnic groups.
Conclusion
Beyond to clinical conditions well known to drive the de-
velopment of hepatotoxicity during NVP treatment, i.e.
HCV coinfection and body mass index, pharmacogenomic
profiles could also play a role in this phenomenon. Our re-
sults suggest the independent role of ABCB1 rs1045642 as
a predictive marker of severe liver toxicity related to NVP.
Further validation studies, to assess possible clinical appli-
cation of this marker in countries in which NVP is still
widely used and/or in patients with other risk factors for
nevirapine related toxicity, are warranted.
Abbreviations
ABCB: ATP Binding Cassette Subfamily B; aOR: Adjusted Odds Ratio;
ART: Antiretroviral treatment; CI: Confidence interval; CYP: Cytochrome P450
enzyme; HIV-1: Human immunodeficiency virus type 1; IQR: Inter quartile
range; NVP: Nevirapine; OR: Odds Ratio; RUCAM: Roussel Uclaf Causality
Assessment Methods; SNPs: Single nucleotide polymorphisms
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Table 5 Backward logistic regression of factors involved in nevirapine induced liver toxicity
OR (95%CI) p aOR (95%CI) p
Male vs Female 0.19 (0.04–0.94) 0.042 0.27 (0.06–1.30) 0.102
Age (× 1 year more) 0.96 (0.88–1.04) 0.293 –
MSM vs HE 0.24 (0.01–4.51) 0.338 –
IVDUs vs HE 2.20 (0.58–8.41) 0.247 –
Other vs HE 1.36 (0.06–29.16) 0.844 –
Caucasian vs Non-Caucasian 0.67 (0.08–5.64) 0.714 –
BMI (× 1 more) 0.70 (0.51–0.94) 0.020 0.72 (0.52–1.00) 0.050
Previous AIDS 0.67 (0.08–5.56) 0.713 –
Previous therapy duration (× 1 year more) 1.05 (0.90–1.23) 0.518 –
CD4 200–500 cell/μL vs < 200 cell/μL 1.17 (0.05–25.7) 0.920 1.51 (0.07–32.23) 0.790
CD4 > 500 cell/μL vs < 200 cell/μL 3.97 (0.21–74.51) 0.357 8.12 (0.42–156.90) 0.166
HIV-RNA (× 1 log10 more) 0.80 (0.54–1.18) 0.260 –
AST (× 1 more) 1.02 (1.01–1.03) 0.008 1.01 (0.99–1.03) 0.144
ALT (× 1 more) 1.01 (1.00–1.02) 0.015 –
HCV coinfection 6.93 (1.38–34.87) 0.019 8.00 (1.27–50.29) 0.027
HBV coinfection 2.39 (0.28–20.36) 0.427 –
ARV Backbone: AZT/DDI/D4T vs ABC 0.73 (0.12–4.47) 0.731 –
ARV Backbone: TDF vs ABC 0.12 (0.01–3.141) 0.204 –
ARV Backbone: Other vs ABC 0.49 (0.02–13.47) 0.672 –
ABCB1 rs1045642 CT/TT vs CC 0.18 (0.04–0.76) 0.020 0.10 (0.02–0.47) 0.004
Abbreviations: OR Odds Ratio, aOR adjusted Odds Ratio, CI confidence interval, HE Heterosexual, MSM Man how have sex with man, IVDUs Intra venous drug users,
BMI Body Mass Index, cps copies, ABC abacavir, TDF tenofovir diproxil fumarate, BMI Body Mass Index, ABCB ATP Binding Cassette Subfamily B
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